Overview
- 4 public-safe observations are available for this inspection.
- 4 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
16 May 2025
21 CFR 211.110(a)
Control procedures to monitor and validate performance
Cited by Bijoy Panicker, Luxuly Abraham
16 May 2025
21 CFR 211.42(c)
Defined areas of adequate size for operations
Cited by Bijoy Panicker, Luxuly Abraham
16 May 2025
21 CFR 211.67(a)
Cleaning / Sanitizing / Maintenance
Cited by Bijoy Panicker, Luxuly Abraham
16 May 2025
FDCA 582(b)(4)
Systems in place to comply with verification requirements
Cited by Bijoy Panicker, Luxuly Abraham
Inspected site
EPEvaric Pharmaceuticals Inc.Hauppauge, United States
Inspection team
LALuxuly Abraham
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.110(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.42(c) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.67(a) | Cited across public-safe Form 483 observations | 1x |
| FDCA 582(b)(4) | Cited across public-safe Form 483 observations | 1x |
Source document
PDF
PDF available
Form 483 source document
The source document is available to authorized Atlas users.
Full 483 report
Get the verbatim text of all 4 observations
The source PDF, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere